Overview of Ivabradine Drug: Use and History

Melviana Lubis


Despite the significant advances in management and prevention, heart failure still cause high mortality and morbidity. Ivabradine is one example of a new drug used in the treatment of heart failure with decreased ejection fraction. Ivabradine history and use is interesting that it can improve our understanding to cardiovascular pathophysiology. There may also be extended indications for Ivabradine use in the future.


ivabradine, If channel blocker

Full Text:



Psotka, M. A., & Teerlink, J. R. (2016). Ivabradine : Role in the chronic heart failure armamentarium. Circulation, 133(21), 20662075.

Badu-Boateng, C., Jennings, R., & Hammersley, D. (2018). The therapeutic role of ivabradine in heart failure. In Therapeutic Advances in Chronic Disease (Vol. 9, Issue 11, pp. 199207). SAGE Publications Ltd.

Baruscotti, M., Bucchi, A., & DiFrancesco, D. (2005). Physiology and pharmacology of the cardiac pacemaker (funny) current. In Pharmacology and Therapeutics (Vol. 107, Issue 1, pp. 5979).

Vilaine, J. P. (2006). The discovery of the selective If current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacological Research, 53(5), 424434.

Borer, J. S., Fox, K., Jaillon, P., & Lerebours, G. (2003). Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation, 107(6), 817823.

Tardif, J.-C., Ponikowski, P., & Kahan, T. (2009). Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. European Heart Journal, 30(5), 540548.

Koruth, J. S., Lala, A., Pinney, S., Reddy, V. Y., & Dukkipati, S. R. (2017). The Clinical Use of Ivabradine. Journal of the American College of Cardiology, 70(14), 17771784.

Ferrari, R. (2015). The ivabradine journey. European Heart Journal, Supplement, 17, G1G9.

Fox, K., Ford, I., Steg, G., Tendera, M., & Ferrari, R. (2008). Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Www.Thelancet.Com, 372.

Swedberg, K., Komajda, M., Bhm, M., Rey, J., Borer, S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010). Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet, 376, 875885.

Fox, K., Ford, I., Steg, P. G., Tardif, J.-C., Tendera, M., & Ferrari, R. (2014). Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. New England Journal of Medicine, 371(12), 10911099.

Bhm, M., Bewarder, Y., Kindermann, I., Slawik, J., Wintrich, J., & Werner, C. (2020). Optimization of Heart Failure Treatment by Heart Rate Reduction. International Journal of Heart Failure, 2(1), 1.

Fala, L. (2016). Ivabradine: A New Oral Option for Treating Heart Failure Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. www.AHDBonline.com

Taub, P. R., Zadourian, A., Lo, H. C., Ormiston, C. K., Golshan, S., & Hsu, J. C. (2021). Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. Journal of the American College of Cardiology, 77(7), 861871.

Bucchi, A., Tognati, A., Milanesi, R., Baruscotti, M., & DiFrancesco, D. (2006). Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. Journal of Physiology, 572(2), 335346.

Bucchi, A., Baruscotti, M., Nardini, M., Barbuti, A., Micheloni, S., Bolognesi, M., & DiFrancesco, D. (2013). Identification of the Molecular Site of Ivabradine Binding to HCN4 Channels. PLoS ONE, 8(1).

DOI: https://doi.org/10.30596/bf.v8i1.12751

DOI (PDF): https://doi.org/10.30596/bf.v8i1.12751.g8465


  • There are currently no refbacks.


Gedung Kampus 1 Universitas Muhammadiyah Sumatera Utara (UMSU) Lantai II, Laboratorium Farmakologi dan Terapi Fakultas Kedokteran UMSU Jalan Gedung Arca No. 53 Medan Sumatera Utara Indonesia, Kode Pos 20217.

Contact (WA): 0812-6208-2844

E-mail: farmatera@umsu.ac.id

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Statcounter View My Stats Buletin Farmatera